Darzalex
Phase 1Small molecule
Qilu Pharmaceutical Co., Ltd.Darzalex is one of 5 small molecule programs targeting Adult Patients With Adverse Risk Acute Myeloblastic Leukemia. It is currently in Phase 1.
2
Indications
10
Total Trials
8
Active Trials
4
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
5 competitors in Peripheral Blood Stem Cell Transplantation
#DrugCompanyPhaseTrials
1Trexall
Jazz PharmaceuticalsPhase 3
Prograf
VVeloxis Pharmaceuticals
Phase 3
Velcade
SShilpa Grover, MD, MPH
Phase 2
Darzalex
Qilu Pharmaceutical Co., Ltd.Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Multiple Myeloma4 trials
Immunogenicity2 trials
Adult1 trial
Peripheral Blood Stem Cell Transplantation1 trial
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
Recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT06398457·8 enrolled
1 more indication
Adult Patients With Adverse Risk Acute Myeloblastic Leukemia1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Darzalex. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details